Uwe Schoenbeck, Ph.D., is Chief Scientific Officer, External Research and Development Innovation (ERDI); and Senior Vice President, Worldwide Research and Development (WRD). ERDI is responsible for identifying and establishing relationships with key external partners to capitalize on complementary areas of expertise. Through these collaborations, ERDI creates unique opportunities for Pfizer researchers and partners to drive the discovery and development of potential new therapies that address areas of high unmet medical need.
“We work closely within the WRD organization on defining the specific needs that each of our therapeutic areas and platform lines has at any given time to focus our outreach against those needs while introducing innovative and disruptive concepts relevant to the organization. Ensuring rigorous scientific and business review of the appropriate substrate is the next critical step, delivering a strong business case on what the outside company will bring to the partnership and what it will take to secure a deal for Pfizer. Matching the right culture and personal chemistry between the parties is key. Pfizer has experienced long lasting success in collaborations where the parties have mutual scientific interests, with both parties bringing something to the table that enables us to do something that neither could do alone.”
Chief Scientific Officer, External Research and Development Innovation; Senior Vice President, Worldwide Research and Development
Uwe Schoenbeck, Ph.D., leads Pfizer's Worldwide Research and Development (WRD) External R&D Innovation (ERDI) team, which identifies and establishes partnerships with pharmaceutical and biotech companies and key academic centers to gain access to cutting-edge science and innovative disease targets, drug candidates and technologies. Dr. Schoenbeck works closely with colleagues across Pfizer, including WRD's research and business units, business development and Pfizer country organizations to harness all opportunities. He is a member of the WRD Leadership Team and sits on Pfizer’s Senior Leadership Council.
In his role, Dr. Schoenbeck oversees integration of exploratory to clinical Proof of Concept small and large molecule drug candidates, as well as technologies to address high unmet medical needs across WRD’s therapeutic areas of focus.
Prior to joining Pfizer in 2009, Dr. Schoenbeck was Vice President, External R&D Innovation for Wyeth Pharmaceuticals where he was responsible for developing and implementing Wyeth’s External R&D strategy and operations. Preceding his time at Wyeth, Dr. Schoenbeck served as Vice President, Cardiovascular Research for Boehringer Ingelheim in Ridgefield, CT, and was responsible for the global cardiovascular research strategy and drug discovery program from target identification to pre-development, including life cycle management for marketed and advanced pipeline products.
Dr. Schoenbeck earned his Ph.D. from the University of Kiel, Germany, and completed postdoctoral training in the Division of Cardiovascular Medicine, Brigham & Women’s Hospital, Harvard Medical School, before joining as a faculty member. He has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, review articles/book chapters and abstracts with particular contributions in molecular and cell biology, cardiovascular research, immunology and metabolism